<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694989</url>
  </required_header>
  <id_info>
    <org_study_id>A83_05BE1918</org_study_id>
    <nct_id>NCT04694989</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386 With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to&#xD;
      evaluate the pharmacokinetics and tolerability of CKD-386 with co-administration of D013,&#xD;
      D326, and D337 in healthy adult volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Actual">May 4, 2021</completion_date>
  <primary_completion_date type="Actual">April 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-386</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>AUCt: Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-386</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CKD-386</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>AUCinf: Area under the concentration-time curve from zero up to ∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-386</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>Tmax: Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf of CKD-386</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>AUCt/AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of CKD-386</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>T1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Hypertension and Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition&#xD;
Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition&#xD;
Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition&#xD;
Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition&#xD;
Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition&#xD;
Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition&#xD;
Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-386</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013, D326, D337</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged ≥ 19 years&#xD;
&#xD;
          2. Weight ≥50kg (man) or 45kg (woman), with calculated body mass index (BMI) of 18 to 30&#xD;
             kg/m2&#xD;
&#xD;
          3. Those who meet the blood pressure criteria during screening tests:&#xD;
&#xD;
               -  Systolic Blood Pressure: 90 to 139 mmHg&#xD;
&#xD;
               -  Diastolic Blood Pressure: 60 to 89 mmHg&#xD;
&#xD;
          4. Those who have no congenital diseases or chronic diseases and have no abnormal&#xD;
             symptoms or findings.&#xD;
&#xD;
          5. Those who are eligible for clinical trials based on laboratory(hematology, blood&#xD;
             chemistry, serology, urology) and 12-lead ECG results at screening.&#xD;
&#xD;
          6. Those who agree to contraception during the participation of clinical trial.&#xD;
&#xD;
          7. Individuals who voluntarily decide to participate and agree to comply with the&#xD;
             cautions after fully understand the detailed description of this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who received investigational products or participated in bioequivalence tests&#xD;
             within 6 months before the first administration of clinical trial drugs.&#xD;
&#xD;
          2. Those who take barbiturate and any related drugs which may cause induction or&#xD;
             inhibition of drug metabolism within 1 month before the first administration of&#xD;
             investigational products.&#xD;
&#xD;
          3. Those who donated whole blood or apheresis within 2 months or 1 month respectfully, or&#xD;
             received blood transfusion within a month.&#xD;
&#xD;
          4. Those who have a history of gastrointestinal surgery except simple appendectomy and&#xD;
             hernia surgery.&#xD;
&#xD;
          5. Those who exceed an alcohol and cigarette consumption than below criteria&#xD;
&#xD;
             • Alcohol: Man_21 glasses/week, Woman_14 glasses/week (1 glass: Soju 50mL, Wine 30mL,&#xD;
             or beer 250mL)&#xD;
&#xD;
             • Smoking: 20 cigarettes/day&#xD;
&#xD;
          6. Patients with the following diseases&#xD;
&#xD;
               -  Patients with hypersensitivity to the main constituents or components of the&#xD;
                  investigational drug&#xD;
&#xD;
               -  Severe hepatic impairment, biliary atresia or cholestasis&#xD;
&#xD;
               -  Patients with hereditary angioedema or with a history of angioedema in the&#xD;
                  treatment of ACE inhibitors or angiotensin II receptor antagonists&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Patients with moderate to severe renal impairment [glomerular filtration rate&#xD;
                  (eGFR) &lt;60 mL / min / 1.73m^2]&#xD;
&#xD;
               -  Renal vascular hypertension patients&#xD;
&#xD;
               -  Patients with active liver disease, including unexplained persistent serum&#xD;
                  transaminase elevations or elevated serum transaminase elevations greater than&#xD;
                  three times the normal upper limit&#xD;
&#xD;
               -  Patients with myopathy or have a history of family or genetic history of myopathy&#xD;
&#xD;
               -  Hypothyroidism&#xD;
&#xD;
               -  If you have a history of muscle toxicity for other HMG-CoA converting enzymes or&#xD;
                  fibrate class drugs&#xD;
&#xD;
          7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency&#xD;
             or glucose-galactose malabsorption.&#xD;
&#xD;
          8. Those who are deemed insufficient to participate in this clinical study by&#xD;
             investigators.&#xD;
&#xD;
          9. Woman who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yook-Hwan Noh, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gwanak-gu</state>
        <zip>08779</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

